LISA MICONI-CORREA: Open Payments
NPI 1376830414 · OGDEN, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$755 in 41 payments from 17 companies in 2025. Trend: 2023 $875 · 2024 $1,037 · 2025 $755
Food & beverage: $655Education: $100
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 13 | $143 |
| Astellas Pharma US Inc | 2 | $116 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $96 |
| AstraZeneca Pharmaceuticals LP | 4 | $65 |
| Lilly USA, LLC | 3 | $50 |
| PFIZER INC. | 2 | $43 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $39 |
| GlaxoSmithKline, LLC. | 2 | $36 |
| Lundbeck LLC | 1 | $24 |
| Janssen Pharmaceuticals, Inc | 1 | $23 |
Products named: VRAYLAR, CAPLYTA, MOUNJARO, NURTEC ODT, XIFAXAN, FARXIGA, QULIPTA, REXULTI.
Industry payments across UT — which companies pay providers there.
